SrasV1, PascalFrancis, Corpus, bibRecord, 000642

Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA

Identifieur interne : 000642 ( PascalFrancis/Corpus ); précédent : 000641; suivant : 000643

Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA

Auteurs : BING NI ; XINFU SHI ; YANG LI ; WENDA GAO ; XILIANG WANG ; YUZHANG WU

Source :

Antiviral therapy : (London) [ 1359-6535 ] ; 2005.

RBID : Pascal:05-0328774

Descripteurs français

Pascal (Inist)
- Réplication, Infection, Syndrome respiratoire aigu sévère, Coronavirus, Plasmide, Interférence ARN.

English descriptors

KwdEn :
- Coronavirus, Infection, Plasmid, RNA interference, Replication, Severe acute respiratory syndrome.

Abstract

Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease caused by a novel coronavirus (SARS-CoV), which spread to over 30 countries in early 2003. Until recently, no specific vaccines and effective drugs have been available to protect patients from infection by this virus. To exploit a new strategy to fight this disease, we investigated the effect of interference RNA (RNAi) on the virus infection and replication with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT), plaque-forming, Western-blot and real-time PCR assays. Results showed that the plasmid-derived siRNAs targeting the non-structural protein 1 (NSP1) sequence of the SARS-CoV genome could specifically inhibit the expression of the NSP1 sequence and effectively suppress the replication and propagation of SARS-CoV in cultured Vero E6 cell lines. The expression of the Spike and Nucleoprotein genes of SARS-CoV at mRNA and protein levels in small interfering (si)RNA-expressing cells was significantly less than that in controls when analysed with PCR and Western-blot assays, 3 days post SARS-CoV infection. Our study provides strong evidence that the NSP1 sequence in the SARS-CoV genome is a valid target for RNAi and the effect of the siRNAs probably mainly resulted from effects on global reduction of subgenome synthesis and subsequent protein expression of SARS-CoV.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1359-6535`
A03		`1`		`@0 Antivir. ther. : (Lond.)`
A05				`@2 10`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA`
A11	`01`	`1`		`@1 BING NI`
A11	`02`	`1`		`@1 XINFU SHI`
A11	`03`	`1`		`@1 YANG LI`
A11	`04`	`1`		`@1 WENDA GAO`
A11	`05`	`1`		`@1 XILIANG WANG`
A11	`06`	`1`		`@1 YUZHANG WU`
A14	`01`			`@1 Institute of Immunology PLA, Third Military Medical University @2 Chongqing @3 CHN @Z 1 aut. @Z 3 aut. @Z 6 aut.`
A14	`02`			`@1 Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS) @2 Beijing @3 CHN @Z 2 aut. @Z 5 aut.`
A14	`03`			`@1 Beth Israel Deaconess Medical Center, Harvard Medical School @2 Boston, MA @3 USA @Z 4 aut.`
A20				`@1 527-533`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 27047 @5 354000124671150070`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 05-0328774`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral therapy : (London)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease caused by a novel coronavirus (SARS-CoV), which spread to over 30 countries in early 2003. Until recently, no specific vaccines and effective drugs have been available to protect patients from infection by this virus. To exploit a new strategy to fight this disease, we investigated the effect of interference RNA (RNAi) on the virus infection and replication with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT), plaque-forming, Western-blot and real-time PCR assays. Results showed that the plasmid-derived siRNAs targeting the non-structural protein 1 (NSP1) sequence of the SARS-CoV genome could specifically inhibit the expression of the NSP1 sequence and effectively suppress the replication and propagation of SARS-CoV in cultured Vero E6 cell lines. The expression of the Spike and Nucleoprotein genes of SARS-CoV at mRNA and protein levels in small interfering (si)RNA-expressing cells was significantly less than that in controls when analysed with PCR and Western-blot assays, 3 days post SARS-CoV infection. Our study provides strong evidence that the NSP1 sequence in the SARS-CoV genome is a valid target for RNAi and the effect of the siRNAs probably mainly resulted from effects on global reduction of subgenome synthesis and subsequent protein expression of SARS-CoV.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Réplication @5 01`
C03	`01`	`X`	`ENG`	`@0 Replication @5 01`
C03	`01`	`X`	`SPA`	`@0 Replicación @5 01`
C03	`02`	`X`	`FRE`	`@0 Infection @5 02`
C03	`02`	`X`	`ENG`	`@0 Infection @5 02`
C03	`02`	`X`	`SPA`	`@0 Infección @5 02`
C03	`03`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 04`
C03	`04`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 04`
C03	`04`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 04`
C03	`05`	`X`	`FRE`	`@0 Plasmide @5 05`
C03	`05`	`X`	`ENG`	`@0 Plasmid @5 05`
C03	`05`	`X`	`SPA`	`@0 Plasmido @5 05`
C03	`06`	`X`	`FRE`	`@0 Interférence ARN @4 CD @5 96`
C03	`06`	`X`	`ENG`	`@0 RNA interference @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 37`
C07	`05`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`05`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`06`	`X`	`FRE`	`@0 Poumon pathologie @5 38`
C07	`06`	`X`	`ENG`	`@0 Lung disease @5 38`
C07	`06`	`X`	`SPA`	`@0 Pulmón patología @5 38`
N21				`@1 234`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0328774 INIST
ET :	Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA
AU :	BING NI; XINFU SHI; YANG LI; WENDA GAO; XILIANG WANG; YUZHANG WU
AF :	Institute of Immunology PLA, Third Military Medical University/Chongqing/Chine (1 aut., 3 aut., 6 aut.); Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS)/Beijing/Chine (2 aut., 5 aut.); Beth Israel Deaconess Medical Center, Harvard Medical School/Boston, MA/Etats-Unis (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Antiviral therapy : (London); ISSN 1359-6535; Royaume-Uni; Da. 2005; Vol. 10; No. 4; Pp. 527-533; Bibl. 26 ref.
LA :	Anglais
EA :	Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease caused by a novel coronavirus (SARS-CoV), which spread to over 30 countries in early 2003. Until recently, no specific vaccines and effective drugs have been available to protect patients from infection by this virus. To exploit a new strategy to fight this disease, we investigated the effect of interference RNA (RNAi) on the virus infection and replication with 3-(4,5-dimethyl-2-thiazolyl)-2,5-dipheny ltetrazolium bromide (MTT), plaque-forming, Western-blot and real-time PCR assays. Results showed that the plasmid-derived siRNAs targeting the non-structural protein 1 (NSP1) sequence of the SARS-CoV genome could specifically inhibit the expression of the NSP1 sequence and effectively suppress the replication and propagation of SARS-CoV in cultured Vero E6 cell lines. The expression of the Spike and Nucleoprotein genes of SARS-CoV at mRNA and protein levels in small interfering (si)RNA-expressing cells was significantly less than that in controls when analysed with PCR and Western-blot assays, 3 days post SARS-CoV infection. Our study provides strong evidence that the NSP1 sequence in the SARS-CoV genome is a valid target for RNAi and the effect of the siRNAs probably mainly resulted from effects on global reduction of subgenome synthesis and subsequent protein expression of SARS-CoV.
CC :	002B02S05
FD :	Réplication; Infection; Syndrome respiratoire aigu sévère; Coronavirus; Plasmide; Interférence ARN
FG :	Virose; Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Poumon pathologie
ED :	Replication; Infection; Severe acute respiratory syndrome; Coronavirus; Plasmid; RNA interference
EG :	Viral disease; Coronaviridae; Nidovirales; Virus; Respiratory disease; Lung disease
SD :	Replicación; Infección; Síndrome respiratorio agudo severo; Coronavirus; Plasmido
LO :	INIST-27047.354000124671150070
ID :	05-0328774

Links to Exploration step

Pascal:05-0328774

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA</title>
<author><name sortKey="Bing Ni" sort="Bing Ni" uniqKey="Bing Ni" last="Bing Ni">BING NI</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Immunology PLA, Third Military Medical University</s1>
<s2>Chongqing</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xinfu Shi" sort="Xinfu Shi" uniqKey="Xinfu Shi" last="Xinfu Shi">XINFU SHI</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS)</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yang Li" sort="Yang Li" uniqKey="Yang Li" last="Yang Li">YANG LI</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Immunology PLA, Third Military Medical University</s1>
<s2>Chongqing</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wenda Gao" sort="Wenda Gao" uniqKey="Wenda Gao" last="Wenda Gao">WENDA GAO</name>
<affiliation><inist:fA14 i1="03"><s1>Beth Israel Deaconess Medical Center, Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiliang Wang" sort="Xiliang Wang" uniqKey="Xiliang Wang" last="Xiliang Wang">XILIANG WANG</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS)</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuzhang Wu" sort="Yuzhang Wu" uniqKey="Yuzhang Wu" last="Yuzhang Wu">YUZHANG WU</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Immunology PLA, Third Military Medical University</s1>
<s2>Chongqing</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0328774</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0328774 INIST</idno>
<idno type="RBID">Pascal:05-0328774</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000642</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA</title>
<author><name sortKey="Bing Ni" sort="Bing Ni" uniqKey="Bing Ni" last="Bing Ni">BING NI</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Immunology PLA, Third Military Medical University</s1>
<s2>Chongqing</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xinfu Shi" sort="Xinfu Shi" uniqKey="Xinfu Shi" last="Xinfu Shi">XINFU SHI</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS)</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yang Li" sort="Yang Li" uniqKey="Yang Li" last="Yang Li">YANG LI</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Immunology PLA, Third Military Medical University</s1>
<s2>Chongqing</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wenda Gao" sort="Wenda Gao" uniqKey="Wenda Gao" last="Wenda Gao">WENDA GAO</name>
<affiliation><inist:fA14 i1="03"><s1>Beth Israel Deaconess Medical Center, Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiliang Wang" sort="Xiliang Wang" uniqKey="Xiliang Wang" last="Xiliang Wang">XILIANG WANG</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS)</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yuzhang Wu" sort="Yuzhang Wu" uniqKey="Yuzhang Wu" last="Yuzhang Wu">YUZHANG WU</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Immunology PLA, Third Military Medical University</s1>
<s2>Chongqing</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral therapy : (London)</title>
<title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title>
<idno type="ISSN">1359-6535</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral therapy : (London)</title>
<title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title>
<idno type="ISSN">1359-6535</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term>
<term>Infection</term>
<term>Plasmid</term>
<term>RNA interference</term>
<term>Replication</term>
<term>Severe acute respiratory syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Réplication</term>
<term>Infection</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Coronavirus</term>
<term>Plasmide</term>
<term>Interférence ARN</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease caused by a novel coronavirus (SARS-CoV), which spread to over 30 countries in early 2003. Until recently, no specific vaccines and effective drugs have been available to protect patients from infection by this virus. To exploit a new strategy to fight this disease, we investigated the effect of interference RNA (RNAi) on the virus infection and replication with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT), plaque-forming, Western-blot and real-time PCR assays. Results showed that the plasmid-derived siRNAs targeting the non-structural protein 1 (NSP1) sequence of the SARS-CoV genome could specifically inhibit the expression of the NSP1 sequence and effectively suppress the replication and propagation of SARS-CoV in cultured Vero E6 cell lines. The expression of the Spike and Nucleoprotein genes of SARS-CoV at mRNA and protein levels in small interfering (si)RNA-expressing cells was significantly less than that in controls when analysed with PCR and Western-blot assays, 3 days post SARS-CoV infection. Our study provides strong evidence that the NSP1 sequence in the SARS-CoV genome is a valid target for RNAi and the effect of the siRNAs probably mainly resulted from effects on global reduction of subgenome synthesis and subsequent protein expression of SARS-CoV.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1359-6535</s0>
</fA01>
<fA03 i2="1"><s0>Antivir. ther. : (Lond.)</s0>
</fA03>
<fA05><s2>10</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BING NI</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>XINFU SHI</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>YANG LI</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WENDA GAO</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>XILIANG WANG</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>YUZHANG WU</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Immunology PLA, Third Military Medical University</s1>
<s2>Chongqing</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS)</s1>
<s2>Beijing</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Beth Israel Deaconess Medical Center, Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>527-533</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27047</s2>
<s5>354000124671150070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0328774</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral therapy : (London)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease caused by a novel coronavirus (SARS-CoV), which spread to over 30 countries in early 2003. Until recently, no specific vaccines and effective drugs have been available to protect patients from infection by this virus. To exploit a new strategy to fight this disease, we investigated the effect of interference RNA (RNAi) on the virus infection and replication with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT), plaque-forming, Western-blot and real-time PCR assays. Results showed that the plasmid-derived siRNAs targeting the non-structural protein 1 (NSP1) sequence of the SARS-CoV genome could specifically inhibit the expression of the NSP1 sequence and effectively suppress the replication and propagation of SARS-CoV in cultured Vero E6 cell lines. The expression of the Spike and Nucleoprotein genes of SARS-CoV at mRNA and protein levels in small interfering (si)RNA-expressing cells was significantly less than that in controls when analysed with PCR and Western-blot assays, 3 days post SARS-CoV infection. Our study provides strong evidence that the NSP1 sequence in the SARS-CoV genome is a valid target for RNAi and the effect of the siRNAs probably mainly resulted from effects on global reduction of subgenome synthesis and subsequent protein expression of SARS-CoV.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Réplication</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Replication</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Replicación</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Infection</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Infection</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Infección</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Plasmide</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Plasmid</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Plasmido</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Interférence ARN</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>RNA interference</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>234</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0328774 INIST</NO>
<ET>Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA</ET>
<AU>BING NI; XINFU SHI; YANG LI; WENDA GAO; XILIANG WANG; YUZHANG WU</AU>
<AF>Institute of Immunology PLA, Third Military Medical University/Chongqing/Chine (1 aut., 3 aut., 6 aut.); Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS)/Beijing/Chine (2 aut., 5 aut.); Beth Israel Deaconess Medical Center, Harvard Medical School/Boston, MA/Etats-Unis (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Antiviral therapy : (London); ISSN 1359-6535; Royaume-Uni; Da. 2005; Vol. 10; No. 4; Pp. 527-533; Bibl. 26 ref.</SO>
<LA>Anglais</LA>
<EA>Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease caused by a novel coronavirus (SARS-CoV), which spread to over 30 countries in early 2003. Until recently, no specific vaccines and effective drugs have been available to protect patients from infection by this virus. To exploit a new strategy to fight this disease, we investigated the effect of interference RNA (RNAi) on the virus infection and replication with 3-(4,5-dimethyl-2-thiazolyl)-2,5-dipheny ltetrazolium bromide (MTT), plaque-forming, Western-blot and real-time PCR assays. Results showed that the plasmid-derived siRNAs targeting the non-structural protein 1 (NSP1) sequence of the SARS-CoV genome could specifically inhibit the expression of the NSP1 sequence and effectively suppress the replication and propagation of SARS-CoV in cultured Vero E6 cell lines. The expression of the Spike and Nucleoprotein genes of SARS-CoV at mRNA and protein levels in small interfering (si)RNA-expressing cells was significantly less than that in controls when analysed with PCR and Western-blot assays, 3 days post SARS-CoV infection. Our study provides strong evidence that the NSP1 sequence in the SARS-CoV genome is a valid target for RNAi and the effect of the siRNAs probably mainly resulted from effects on global reduction of subgenome synthesis and subsequent protein expression of SARS-CoV.</EA>
<CC>002B02S05</CC>
<FD>Réplication; Infection; Syndrome respiratoire aigu sévère; Coronavirus; Plasmide; Interférence ARN</FD>
<FG>Virose; Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Poumon pathologie</FG>
<ED>Replication; Infection; Severe acute respiratory syndrome; Coronavirus; Plasmid; RNA interference</ED>
<EG>Viral disease; Coronaviridae; Nidovirales; Virus; Respiratory disease; Lung disease</EG>
<SD>Replicación; Infección; Síndrome respiratorio agudo severo; Coronavirus; Plasmido</SD>
<LO>INIST-27047.354000124671150070</LO>
<ID>05-0328774</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000642 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000642 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0328774
   |texte=   Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA

Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri